40 CFR Ch. I (7–1–98 Edition) Pt. 414, App. A
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
An Aged Reaction Revisited
TETRAHEDRON Pergamon Tetrahedron 56 (2000) 9705±9711 2-Alkyl-4,6-dialkylamino-1,3,5-triazines via Grignard Alkylation of Cyanuric Chloride: An Aged Reaction Revisited Rita Menicagli,* Simona Samaritani and Valeria Zucchelli Dipartimento di Chimica e Chimica Industriale and Centro di Studi del CNR per le Macromolecole Stereordinate ed Otticamente Attive, Via Risorgimento 35, 56126 Pisa, Italy Received 24 July 2000; revised 8 September 2000; accepted 28 September 2000 AbstractÐSuitable one-pot reaction conditions are suggested to prepare, in good overall yields, some 2-(alk-1 0-ynyl)- and 2-alkyl-4,6- dialkylamino-1,3,5-triazines via reaction of cyanuric chloride with Grignard reagents followed by amination. q 2000 Elsevier Science Ltd. All rights reserved. In our studies1 concerning the protection of paper against The reaction between a benzene (CAUTION) solution of 1 pathogenic fungi, we found that 2-(alk-1 0-ynyl)-4,6- and a THF solution of alk-1 0-ynylmagnesium halides has dimethoxy-1,3,5-triazines showed an appreciable biostatic been reported to afford 2-(alk-1 0-ynyl)-4,6-dichloro-1,3,5- activity.2 Taking into account that alkylamino derivatives of triazines in 50±60% yield.6a Since the puri®cation of these 1,3,5-triazine are generally better biostatic agents than intermediates might have caused an appreciable loss of the alkoxy derivatives,1 preparation of 2-(alk-1 0-ynyl)-4,6- product owing to the well known8 reactivity of the C±Cl dialkylamino-1,3,5-triazines was necessary in order to bonds and the treatment of the crude products with nucleo- compare their antifungal activities with those of 2-(alk-1 0- philes would have lead to complex mixtures of compounds, ynyl)-4,6-dimethoxy-1,3,5-triazines. -
United States Patent Office Patented Apr
2,881,193 United States Patent Office Patented Apr. 7, 1959 2 propionic acid, glutamic acid, aspartic acid and the like. 2,881,193 Particularly satisfactory results are obtained in the PURIFICATION OF N-HIGHER FATTY ACED purification of N-higher fatty acyl sarcosine compounds AMDES OF LOWER MONOAMINOCAR such as salts of N-lauroyl sarcosine, N-myristoyl sarcosine BOXYFLIC ACDS and N-palmitoyl sarcosine, e.g., sodium, potassium salts thereof. Morton Batlan Epstein, Linden, N.J., assignor to Colgate While the present invention is broadly applicable to Palmolive Company, Jersey City, N.J., a corporation mixtures of the amide and higher fatty acid material of Delaware as indicated, it is effective particularly with the reaction No Drawing. Application May 9, 1955 product produced in the following manner and results Serial No. 507,177 in an amide material substantially free from soap and the like. Thus, the amide may be formed by condensing 6 Claims. (C. 260-404) a higher fatty acyl halide with a salt of said amino car boxylic acid, which has a primary or secondary amino The present invention relates to a novel process for 5 group, in an aqueous alkaline medium. purifying N-higher. acyl amide compounds. More This condensation reaction may be performed under specifically the invention is of a method for removing various suitable conditions. The reaction may be con impurities of the fatty acid or soap type from compounds ducted by mixing suitable proportions of the reactants which are N-higher fatty amides of lower monoamino in an aqueous medium. In general, the reaction is effected carboxylic acids or salts thereof. -
The Impact of D-Cycloserine and Sarcosine on in Vivo Frontal Neural
Yao et al. BMC Psychiatry (2019) 19:314 https://doi.org/10.1186/s12888-019-2306-1 RESEARCH ARTICLE Open Access The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model Lulu Yao1, Zongliang Wang1, Di Deng1, Rongzhen Yan1, Jun Ju1 and Qiang Zhou1,2* Abstract Background: N-methyl-D-aspartate receptor (NMDAR) hypofunction has been proposed to underlie the pathogenesis of schizophrenia. Specifically, reduced function of NMDARs leads to altered balance between excitation and inhibition which further drives neural network malfunctions. Clinical studies suggested that NMDAR modulators (glycine, D-serine, D-cycloserine and glycine transporter inhibitors) may be beneficial in treating schizophrenia patients. Preclinical evidence also suggested that these NMDAR modulators may enhance synaptic NMDAR function and synaptic plasticity in brain slices. However, an important issue that has not been addressed is whether these NMDAR modulators modulate neural activity/spiking in vivo. Methods: By using in vivo calcium imaging and single unit recording, we tested the effect of D-cycloserine, sarcosine (glycine transporter 1 inhibitor) and glycine, on schizophrenia-like model mice. Results: In vivo neural activity is significantly higher in the schizophrenia-like model mice, compared to control mice. D-cycloserine and sarcosine showed no significant effect on neural activity in the schizophrenia-like model mice. Glycine induced a large reduction in movement in home cage and reduced in vivo brain activity in control mice which prevented further analysis of its effect in schizophrenia-like model mice. Conclusions: We conclude that there is no significant impact of the tested NMDAR modulators on neural spiking in the schizophrenia-like model mice. -
SAFETY DATA SHEET Nonflammable Gas Mixture: Cyanogen Chloride 1-999Ppm / Nitrogen 99%
SAFETY DATA SHEET Nonflammable Gas Mixture: Cyanogen Chloride 1-999ppm / Nitrogen 99% Section 1. Identification GHS product identifier : Nonflammable Gas Mixture: Cyanogen Chloride 1-999ppm / Nitrogen 99% Other means of : Not available. identification Product use : Synthetic/Analytical chemistry. SDS # : 012226 Supplier's details : Airgas USA, LLC and its affiliates 259 North Radnor-Chester Road Suite 100 Radnor, PA 19087-5283 1-610-687-5253 24-hour telephone : 1-866-734-3438 Section 2. Hazards identification OSHA/HCS status : This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200). Classification of the : GASES UNDER PRESSURE - Compressed gas substance or mixture GHS label elements Hazard pictograms : Signal word : Warning Hazard statements : Contains gas under pressure; may explode if heated. May displace oxygen and cause rapid suffocation. Precautionary statements General : Read and follow all Safety Data Sheets (SDS’S) before use. Read label before use. Keep out of reach of children. If medical advice is needed, have product container or label at hand. Close valve after each use and when empty. Use equipment rated for cylinder pressure. Do not open valve until connected to equipment prepared for use. Use a back flow preventative device in the piping. Use only equipment of compatible materials of construction. Prevention : Not applicable. Response : Not applicable. Storage : Protect from sunlight when ambient temperature exceeds 52°C/125°F. Store in a well- ventilated place. Disposal : Not applicable. Hazards not otherwise : In addition to any other important health or physical hazards, this product may displace classified oxygen and cause rapid suffocation. Section 3. Composition/information on ingredients Substance/mixture : Mixture Other means of : Not available. -
Methods for the Determination of Chlorine, Hydrogen-Sulfide, and Hydrogen-Cyanide Utilizing Permeation Sampling
Louisiana State University LSU Digital Commons LSU Historical Dissertations and Theses Graduate School 1981 Methods for the Determination of Chlorine, Hydrogen-Sulfide, and Hydrogen-Cyanide Utilizing Permeation Sampling. James Keith Hardy Louisiana State University and Agricultural & Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses Recommended Citation Hardy, James Keith, "Methods for the Determination of Chlorine, Hydrogen-Sulfide, and Hydrogen-Cyanide Utilizing Permeation Sampling." (1981). LSU Historical Dissertations and Theses. 3599. https://digitalcommons.lsu.edu/gradschool_disstheses/3599 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact [email protected]. INFORMATION TO USERS This was produced from a copy of a document sent to us for microfilming. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the material submitted. The following explanation of techniques is provided to help you understand markings or notations which may appear on this reproduction. 1.The sign or “target” for pages apparently lacking from the document photographed is “Missing Page(s)”. If it was possible to obtain the missing page(s) or section, they are spliced into the Him along with adjacent pages. This may have necessitated cutting through an image and. duplicating adjacent pages to assure you of complete continuity. 2. When an image on the Him is obliterated with a round black mark it is an indication that the film inspector noticed either blurred copy because of movement during exposure, or duplicate copy. -
Toxicological Profile for Cyanide
CYANIDE 141 5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 5.1 PRODUCTION The demand for hydrogen cyanide in the United States during 2000 was 1.615 billion pounds, up slightly from 1.605 billion pounds in 1999 (CMR 2001). Production of hydrogen cyanide in 2003 was 2.019 billion pounds in the United States (FAS 2005). The demand for hydrogen cyanide was projected to be 1.838 billion pounds in 2004 (CMR 2001; NYSDOH 2005). Major producers of hydrogen cyanide are Adisseo USA, Inc. (Institute, West Virginia); Cyanco Co. (Winnemucca, Nevada); Cytec Industries (Waggoman, Louisiana); Degussa Corp. (Theodora, Alabama); The Dow Chemical Company (Freeport, Texas); E.I. du Pont de Neumours and Company (Memphis, Tennessee; Beaumont, Texas); Innovene (Green Lake, Texas and Lima, Ohio); Invista, Inc. (Orange, Texas and Victoria, Texas); Rhom and Haas Texas Inc. (Deer Park, Texas); Solutia, Inc. (Alvin, Texas); Sterling Chemicals, Inc. (Texas City, Texas); and Syngenta Crop Protection (St. Garbiel, Louisiana) (SRI 2005). The combined annual production capacity of these plants is approximately 2.036 billion pounds (SRI 2005). As of February 2005, the following companies produced other cyanide compounds in the United States (SRI 2005): ammonium Crompton, Taft, Louisiana; and Mallinckrodt, Inc., St. Louis, Missouri thiocyanate: cyanogen: Matheson Gas Products, Inc., Gloucester, Massachusetts potassium cyanide: DuPont Chemical Company, Memphis, Tennessee; and The Dow Chemical Company, Nashua, New Hampshire potassium silver Engelhard Corporation, Union, New Jersey; and Metalor Technologies USA, North cyanide: Attleboro, Massachusetts Facilities in the United States producing sodium cyanide and their annual capacity (in millions of pounds) in 2005 include: Cyanco Co., Winnemucca, Nevada (86); and E.I. -
Abbreviations of Chemical Warfare Agents, 152 Acetylcholinesterase
Index Abbreviations of chemical warfare agents, Blood ChE inhibition, nerve agent critical 152 toxic effect on, 23 Acetylcholinesterase (AChE) inhibition, Blood ChE inhibition, nerve agent species nerve agents and, 18 variation of, 21 Acetylthiocholine iodide, RBC-ChE activ Blood cholinesterases, nerve agent effects ity and, 22 on, 20 AChE (acetylcholinesterase) inhibition, Butyrylcholinesterase (plasma-ChE), nerve agents and, 18 nerve agent effects on, 20 Acronyms for chemical warfare agents, 152 Acute inhalation toxicity, CK and, 114 Carboxylesterases (aliesterases), nerve Acute toxicity, CK (cyanogen chloride) agent effects on, 21 and, 113 Carcinogenicity, CK and, 122 Acute toxicity, GA and, 68 Carcinogenicity, GA and, 73 Acute toxicity, GB and, 78 Carcinogenicity, GB and, 90 Acute toxicity, GD and, 94 Carcinogenicity, HD and, 38 Acute toxicity, HD and, 30 Carcinogenicity, HN2 and, 53 Acute toxicity, HN2 and, 51 Carcinogenicity, HT and, 49 Acute toxicity, HT and, 49 Carcinogenicity, lewisite and, 107 Acute toxicity, lewisite and, 103 Carcinogenicity, VX and, 61 Acute toxicity, T sulfur mustard and, 50 ChE (cholinesterase), nerve agent effects Acute toxicity, VX and, 54 on, 20 Agent CK, see CK or cyanogen chloride ChE inhibition, nerve agent potency on, Agent GA, see GA or Tabun 23 Agent GB, see GB or Sarin Chemical warfare agent disposal tech Agent GD, see GD or Soman niques,3 Agent HD, see HD or Sulfur mustard HD Chemical warfare agent non-stockpile Agent HN2, see HN2 or Nitrogen mus- sites U.S., 4 tard Chemical warfare agents, 1 ff. Agent HT, see HT or Sulfur mustard HT Chemical warfare agents, acronyms/abbre Agent L, see L or Lewsite viations of, 152 Agent T, see T Sulfur mustard Chemical warfare agents, air exposure lim Agent VX, see VX its of, 7 Aliesterases (carboxylesterases), nerve Chemical warfare agents, environmental agent effects on, 21 cleanup of, 3 Anticholinesterase agents, 18 Chemical warfare agents, environmental Army chemical destruction, 3 ff. -
Threshold Limit Values (TLV) and Immediately Dangerous to Life and Health (IDLH) Values
Reference Information 442 Threshold Limit Values (TLV) and Immediately Dangerous to Life and Health (IDLH) values Matheson Tri-Gas assumes no responsibility for the accuracy of the TLV TLV information listed. As TLV and IDLH values may change, the current Substance TWA STEL IDLH guidelines from the following sources should be consulted for up-to-date accuracy. Fluorine 1 2 25 Formaldehyde - 0.3C 20 Sources: TLV-TWA and TLV-STEL data extracted from the 2005 Threshold Limit Values & Biological Exposure Indices, copyright 2005 by the American Conference of Formic Acid 5 10 30 Governmental Industrial Hygienists (ACGIH). IDLH values extracted from the Furfural 2 - 100 NIOSH Pocket Guide to Chemical Hazards, 2004 published by the National Institute Gasoline 300 500 - for Occupational Safety and Health (NIOSH). Germanium tetrahydride 0.2 - - Note: All concentrations in parts per million (ppm) unless otherwise noted. Glutaraldehyde - 0.05C - “C” indicates Ceiling Limit. Heptane 400 500 750 TLV TLV n-Hexane 50 - 1,100 Substance TWA STEL IDLH Hydrazine 0.01 - 50 Acetaldehyde - 25C 2,000 Hydrogen Bromide - 2C 30 Acetic Acid 10 15 50 Hydrogen Chloride - 2C 50 Acetone 500 750 2,500 Hydrogen Cyanide - 4.7C 50 Acetonitirle 20 - 500 Hydrogen Fluoride 0.5 2C 30 Acrolein - 0.1C 2 Hydrogen Peroxide 1 - 75 Acrylonitrile 2 - 85 Hydrogen Selenide 0.05 - 1 Ammonia 25 35 300 Hydrogen Sulfide 10 15 100 Arsine 0.05 - 3 Iodine - 0.1C 2 Benzene 0.5 2.5 500 Isopropyl Alcohol 200 400 2,000 Boron Trifluoride - 1C 25 Methyl Alcohol 200 250 6,000 Bromine 0.1 0.2 3 Methylamine -
NIOSH Guidance -Filtration and Air Cleaning Systems to Protect Building
Guidance for Filtration and Air-Cleaning Systems to Protect Building Environments from Airborne Chemical, Biological, or Radiological Attacks Department of Health and Human Services Centers for Disease Control and Prevention National Institute for Occupational Safety and Health April 2003 ii Ordering Information To receive documents or other information about occupational safety and health topics, contact the National Institute for Occupational Safety and Health (NIOSH) at NIOSH Publications Dissemination 4676 Columbia Parkway Cincinnati, OH 45226-1998 Telephone: 1-800-35-NIOSH (1-800-356-4674) Fax: 1-513-533-8573 E-mail: [email protected] or visit the NIOSH Web site at www.cdc.gov/niosh This document is in the public domain and may be freely copied or reprinted. Disclaimer: Mention of any company, product, policy, or the inclusion of any reference does not constitute endorse- ment by NIOSH. DHHS (NIOSH) Publication No. 2003-136 iii Foreword The Occupational Safety and Health Act of 1970 [Public Law 91-596] assures so far as possible every working man and woman in the Nation safe and healthful working conditions. The Act charges the National Institute for Occupational Safety and Health (NIOSH) with conducting research and making science-based recommenda- tions to prevent work-related illness, injury, disability, and death. On October 8, 2001, the President of the United States established by executive order the Office of Homeland Security (OHS), which is mandated “to develop and coordinate the implementation of a com- prehensive national strategy to secure the United States from ter- rorist threats or attacks.” In January 2002, the OHS formed the Interagency Workgroup on Building Air Protection under the Medical and Public Health Preparedness Policy Coordinating Committee of the OHS. -
Incorporation of Sarcosine Into the Actinomycins Synthesized by Streptomyces Antibioticus
82 Biochem. J. (1964) 90, 82 Incorporation of Sarcosine into the Actinomycins Synthesized by Streptomyces antibioticus By 0. CIFERRI, A. ALBERTINI AND G. CASSANI Department of Genetics, University of Pavia, Italy (Received 3 April 1963) Sarcosine is an amino acid apparently not Micro-organism. Streptomyces antibioticus (no. 1692 of widely distributed in Nature. As a free amino acid, the Culture Collection of the Botanical Institute of this sarcosine has been demonstrated in the radial University) was maintained on slants ofEmerson's medium caeca of the starfish Astropecten aurantiacus (Emerson, Whiffen, Bohonas & DeBoer, 1946). A suspen- sion of spores from such slants was used to inoculate the (Kossel & Edlbacher, 1915), in the muscles of vegetative medium: soya-bean flour 20 g., glucose 10 g., Elasmobranchii (Tarr, 1958) and in the reindeer tap water 1000 ml. (adjusted to pH 7-4 with N-NaOH). The moss, Cladonia itlvatica (Linko, Alfthan, Miettinen culture was incubated at 280 for 48 hr. on an alternating & Virtanen, 1953). Sarcosine has been found shaker. The cells were recovered by centrifuging in the bound in peptides in the antibiotics of the actino- cold, washed twice with the fermentation medium (see mycin (Dalgliesh, Johnson, Todd & Vining, 1950) below) and suspended in the same solution to give a cell and etamycin (Sheehan, Zachau & Lawson, 1957) concentration twice that of the vegetative-medium suspen- groups. The reported presence of sarcosine in the sion. A portion (5 ml.) of this suspension was used to hydrolysate of groundnut protein (Haworth, inoculate 100 ml. of the synthetic galactose-glutamic acid ('fermentation') medium (Katz & Goss, 1960). -
230 Subpart K—Indirect Discharge Point Sources
§ 414.110 40 CFR Ch. I (7±1±00 Edition) [52 FR 42568, Nov. 5, 1987, as amended at 58 PSES and PSNS 1 FR 36893, July 9, 1993] Maximum Effluent characteristics Maximum for any for any monthly Subpart KÐIndirect Discharge one day average Point Sources Acenaphthene ................................... 47 19 Anthracene ........................................ 47 19 SOURCE: 58 FR 36893, July 9, 1993, unless Benzene ............................................ 134 57 otherwise noted. Bis(2-ethylhexyl) phthalate ................ 258 95 Carbon Tetrachloride ......................... 380 142 § 414.110 Applicability; description of Chlorobenzene .................................. 380 142 Chloroethane ..................................... 295 110 the subcategory of indirect dis- Chloroform ......................................... 325 111 charge point sources. Di-n-butyl phthalate ........................... 43 20 1,2-Dichlorobenzene .......................... 794 196 The provisions of this subpart are ap- 1,3-Dichlorobenzene .......................... 380 142 plicable to the process wastewater dis- 1,4-Dichlorobenzene .......................... 380 142 charges resulting from the manufac- 1,1-Dichloroethane ............................ 59 22 ture of the OCPSF products and prod- 1,2-Dichloroethane ............................ 574 180 1,1-Dichloroethylene .......................... 60 22 uct groups defined by § 414.11 from any 1,2-trans-Dichloroethylene ................. 66 25 indirect discharge point source. 1,2-Dichloropropane ......................... -
A Pilot Open-Label Trial of Use of the Glycine Transporter I Inhibitor
nal atio Me sl d n ic a in r e T Yang, et al., Transl Med (Sunnyvale) 2014, 4:2 Translational Medicine DOI: 10.4172/2161-1025.1000127 ISSN: 2161-1025 Research Article Open Access A Pilot Open-Label Trial of Use of the Glycine Transporter I Inhibitor, Sarcosine, in High-Functioning Children with Autistic Disorder Pinchen Yang1, Hsien-Yuan Lane2, Cheng-Fang Yen1, Chen-Lin Chang 3,4* 1Department of Psychiatry, College of Medicine, Kaohsiung Medical University and Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 2Institute of Clinical Medical Science & Departments of Psychiatry, China Medical University and Hospital, Taichung, Taiwan 3Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University and Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 4Department of Psychiatry, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan *Corresponding author: Chen-Lin Chang, 100, Shin Chuan 1 st Rd, Kaohsiung 807, Taiwan, Graduate Institute of Medicine, Kaohsiung Medical University and Kaohsiung Medical University Hospital & Department of Psychiatry, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, Tel:+886-9-36360220; Fax: +886-7-3134761; E-mail: [email protected] Rec date: Apr 01, 2014; Acc date: Apr 17, 2014; Pub date: Apr 22, 2014 Copyright: © 2014 Yang P et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract This open-label trial examined the efficacy and safety of a glycine transporter I inhibitor, sarcosine, in the 24-week treatment of high-functioning children with autistic disorder.